|
EP0430968B1
(en)
*
|
1988-05-02 |
1996-11-20 |
PHANOS TECHNOLOGIES, Inc. |
Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
|
|
US5264618A
(en)
*
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
|
US5792751A
(en)
*
|
1992-04-13 |
1998-08-11 |
Baylor College Of Medicine |
Tranformation of cells associated with fluid spaces
|
|
JPH09500013A
(en)
|
1993-06-01 |
1997-01-07 |
ライフ・テクノロジーズ・インコーポレイテッド |
Gene immunity with cationic lipids
|
|
US5674908A
(en)
|
1993-12-20 |
1997-10-07 |
Life Technologies, Inc. |
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
|
|
US6057299A
(en)
*
|
1994-01-13 |
2000-05-02 |
Calydon, Inc. |
Tissue-specific enhancer active in prostate
|
|
US5830686A
(en)
*
|
1994-01-13 |
1998-11-03 |
Calydon |
Tissue-specific enhancer active in prostate
|
|
US5928944A
(en)
*
|
1994-02-04 |
1999-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of adenoviral-medicated cell transfection
|
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
|
US5746223A
(en)
|
1996-10-11 |
1998-05-05 |
Williams; Kevin Jon |
Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
|
|
US6139871A
(en)
*
|
1995-07-26 |
2000-10-31 |
The University Of British Columbia |
Liposome compositions and methods for the treatment of atherosclerosis
|
|
US6773719B2
(en)
|
1994-03-04 |
2004-08-10 |
Esperion Luv Development, Inc. |
Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
|
|
US6312719B1
(en)
|
1994-03-04 |
2001-11-06 |
The University Of British Columbia |
Liposome compositions and methods for the treatment of atherosclerosis
|
|
US6995008B1
(en)
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
|
US6100242A
(en)
|
1995-02-28 |
2000-08-08 |
The Regents Of The University Of California |
Gene therapies for enhancing cardiac function
|
|
US6752987B1
(en)
|
1995-02-28 |
2004-06-22 |
The Regents Of The University Of California |
Adenovirus encoding human adenylylcyclase (AC) VI
|
|
US20020103147A1
(en)
|
1997-09-05 |
2002-08-01 |
Hammond H. Kirk |
Gene therapy for congestive heart failure
|
|
CA2237316C
(en)
|
1995-11-30 |
2012-06-26 |
Vical Incorporated |
Complex cationic lipids
|
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
|
US7384923B2
(en)
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
|
ES2187812T3
(en)
*
|
1996-09-13 |
2003-06-16 |
Lipoxen Technologies Ltd |
COMPOSITION OF LIPOSOMES.
|
|
EP0954585B1
(en)
|
1996-10-01 |
2009-11-25 |
Geron Corporation |
Human telomerase reverse transcriptase promoter
|
|
CA2297489A1
(en)
|
1997-07-30 |
1999-02-11 |
Emory University |
Novel bone mineralization proteins, dna, vectors, expression systems
|
|
FR2766706B1
(en)
*
|
1997-07-30 |
2001-05-25 |
Biovector Therapeutics Sa |
STABLE PARTICULATE COMPLEXES OF NEUTRAL OR NEGATIVE GLOBAL LOAD OF MULTILAMELLAR STRUCTURE COMPOSED OF AT LEAST ONE BIOLOGICALLY ACTIVE GLOBALLY ANIONIC SUBSTANCE AND A CATIONIC COMPONENT, THEIR PREPARATION AND USE
|
|
FR2766705B1
(en)
*
|
1997-07-30 |
2001-05-25 |
Biovector Therapeutics |
PARTICLE COMPLEX OF NEUTRAL OR NEGATIVE GLOBAL CHARGE FORMED OF A CATIONIC OR NEUTRAL VESICLE AND A BIOLOGICALLY ACTIVE ANIONIC SUBSTANCE, THEIR PREPARATION AND THEIR USE
|
|
AU8692598A
(en)
|
1997-08-04 |
1999-02-22 |
Calydon, Inc. |
A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
|
|
US7462605B2
(en)
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
|
JP2002500880A
(en)
|
1998-01-23 |
2002-01-15 |
ニューバイオティックス インコーポレイテッド |
Therapeutic agents catalyzed by enzymes
|
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
DE69928244T2
(en)
|
1998-05-06 |
2006-08-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. |
INHIBITORS OF NF-KB ACTIVATION
|
|
PT1129064E
(en)
|
1998-11-12 |
2008-01-31 |
Invitrogen Corp |
Transfection reagents
|
|
US7868162B2
(en)
|
1998-12-30 |
2011-01-11 |
Lakewood-Amedex, Inc. |
Antimicrobial and antiviral compounds and methods for their use
|
|
US6627215B1
(en)
|
1998-12-30 |
2003-09-30 |
Oligos Etc. Inc. |
Devices for improved wound management
|
|
US20020032164A1
(en)
|
1998-12-30 |
2002-03-14 |
Dale Roderic M. K. |
Antimicrobial compounds and methods for their use
|
|
US6723338B1
(en)
|
1999-04-01 |
2004-04-20 |
Inex Pharmaceuticals Corporation |
Compositions and methods for treating lymphoma
|
|
US7244450B2
(en)
|
1999-04-01 |
2007-07-17 |
Inex Pharmaceuticals Corporation |
Compositions and methods for treating lymphoma
|
|
DE60042968D1
(en)
|
1999-04-01 |
2009-10-29 |
Hana Biosciences Inc |
COMPOSITIONS AND METHODS OF TREATING LYMPHOMA
|
|
US7311924B2
(en)
|
1999-04-01 |
2007-12-25 |
Hana Biosciences, Inc. |
Compositions and methods for treating cancer
|
|
US20030083273A1
(en)
*
|
1999-04-20 |
2003-05-01 |
Tod M. Woolf |
Antisense oligomers
|
|
US6683061B1
(en)
|
1999-07-22 |
2004-01-27 |
Newbiotics, Inc. |
Enzyme catalyzed therapeutic activation
|
|
WO2001007088A2
(en)
|
1999-07-22 |
2001-02-01 |
Newbiotics, Inc. |
Methods for treating therapy-resistant tumors
|
|
KR20020086508A
(en)
|
2000-02-08 |
2002-11-18 |
상가모 바이오사이언스 인코포레이티드 |
Cells for drug discovery
|
|
CA2441350A1
(en)
|
2001-01-19 |
2002-07-25 |
Newbiotics, Inc. |
Methods to treat autoimmune and inflammatory conditions
|
|
JP4252446B2
(en)
|
2001-06-22 |
2009-04-08 |
フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） |
Hepatitis protection mediated by ABIN
|
|
IL159722A0
(en)
|
2001-07-10 |
2004-06-20 |
Oligos Etc Inc |
Pharmaceutical compositions containing oligonucleotides
|
|
EP1435779A4
(en)
|
2001-09-24 |
2005-06-01 |
Sangamo Biosciences Inc |
Modulation of stem cells using zinc finger proteins
|
|
EP1474444A1
(en)
|
2002-01-10 |
2004-11-10 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
A novel splice variant of myd88 and uses thereof
|
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
WO2003064626A2
(en)
|
2002-02-01 |
2003-08-07 |
Sequitur, Inc. |
Double-stranded oligonucleotides
|
|
US7273620B1
(en)
|
2002-05-20 |
2007-09-25 |
University Of British Columbia |
Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
|
|
US7135324B2
(en)
|
2002-09-04 |
2006-11-14 |
The University Of Connecticut |
Viral recombinases, related articles, and methods of use thereof
|
|
DE10322123A1
(en)
*
|
2003-05-12 |
2004-12-16 |
Novosom Ag |
Stable anionic liposome depot system for prolonged release of protein or peptide drugs, e.g. insulin, comprising phosphatidyl choline, cholesterol, anionic lipid(s) and cationic polymer
|
|
WO2005014791A2
(en)
|
2003-08-08 |
2005-02-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
CA2539439C
(en)
|
2003-09-19 |
2012-10-23 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
JP4564052B2
(en)
|
2004-04-08 |
2010-10-20 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Methods and compositions for modulating myocardial contractility
|
|
AU2005251691A1
(en)
|
2004-05-17 |
2005-12-22 |
Tekmira Pharmaceuticals Corporation |
Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
|
|
CA2579677A1
(en)
|
2004-09-16 |
2006-03-30 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
|
US9315862B2
(en)
|
2004-10-05 |
2016-04-19 |
California Institute Of Technology |
Aptamer regulated nucleic acids and uses thereof
|
|
JP4988606B2
(en)
|
2005-02-28 |
2012-08-01 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Anti-angiogenic methods and compositions
|
|
WO2006130974A1
(en)
|
2005-06-08 |
2006-12-14 |
Cangene Corporation |
Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
|
|
CA2615532C
(en)
|
2005-07-26 |
2016-06-28 |
Sangamo Biosciences, Inc. |
Targeted integration and expression of exogenous nucleic acid sequences
|
|
WO2007039454A1
(en)
|
2005-09-20 |
2007-04-12 |
Basf Plant Science Gmbh |
Methods for controlling gene expression using ta-siran
|
|
NZ598088A
(en)
|
2005-10-21 |
2013-09-27 |
Univ California |
C-kit oncogene mutations in melanoma
|
|
WO2007062399A2
(en)
|
2005-11-23 |
2007-05-31 |
The Board Of Regents Of The University Of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
|
AU2006326940B2
(en)
|
2005-12-22 |
2012-04-19 |
Vib Vzw |
Means and methods for mediating protein interference
|
|
US8669418B2
(en)
|
2005-12-22 |
2014-03-11 |
Vib Vzw |
Means and methods for mediating protein interference
|
|
JP5266210B2
(en)
|
2006-05-25 |
2013-08-21 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Modified cleavage half-domain
|
|
WO2008058291A2
(en)
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
|
CN101883850B
(en)
|
2007-07-12 |
2014-11-12 |
桑格摩生物科学股份有限公司 |
Methods and compositions for inactivating alpha-1,6 fucosyltransferase (FUT 8) gene expression
|
|
US8367815B2
(en)
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
|
US8865667B2
(en)
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
US9029524B2
(en)
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
|
SG188866A1
(en)
|
2007-12-11 |
2013-04-30 |
Scripps Research Inst |
Compositions and methods related to mrna translational enhancer elements
|
|
JP5697993B2
(en)
|
2008-02-11 |
2015-04-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
Modified RNAi polynucleotides and uses thereof
|
|
WO2009151591A2
(en)
|
2008-06-10 |
2009-12-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
|
KR20160015400A
(en)
|
2008-08-22 |
2016-02-12 |
상가모 바이오사이언스 인코포레이티드 |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
JP2012502991A
(en)
|
2008-09-22 |
2012-02-02 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
RNA interference in dermal applications
|
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
|
JP5681114B2
(en)
|
2008-12-04 |
2015-03-04 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Rat genome editing using zinc finger nuclease
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
US8551945B2
(en)
|
2009-02-04 |
2013-10-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
|
WO2010101628A2
(en)
|
2009-03-02 |
2010-09-10 |
Massachusetts Institute Of Technology |
Methods and products for in vivo enzyme profiling
|
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
|
AU2010235161B2
(en)
|
2009-04-09 |
2015-01-22 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
WO2010148010A1
(en)
|
2009-06-15 |
2010-12-23 |
4S3 Bioscience Inc. |
Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides
|
|
EP2461819A4
(en)
|
2009-07-28 |
2013-07-31 |
Sangamo Biosciences Inc |
Methods and compositions for treating trinucleotide repeat disorders
|
|
DK2462230T3
(en)
|
2009-08-03 |
2015-10-19 |
Recombinetics Inc |
METHODS AND COMPOSITIONS FOR TARGETED RE-MODIFICATION
|
|
EP2485768A1
(en)
|
2009-10-07 |
2012-08-15 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding lipid compounds
|
|
UA118328C2
(en)
|
2010-01-22 |
2019-01-10 |
Дау Агросайєнсіз Ллс |
Targeted gemomic alteration
|
|
PT2534173T
(en)
|
2010-02-08 |
2019-10-31 |
Sangamo Therapeutics Inc |
Engineered cleavage half-domains
|
|
EP2660318A1
(en)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
EP3560503B1
(en)
|
2010-03-24 |
2021-11-17 |
Phio Pharmaceuticals Corp. |
Rna interference in dermal and fibrotic indications
|
|
CN103200945B
(en)
|
2010-03-24 |
2016-07-06 |
雷克西制药公司 |
RNA interference in ocular syndromes
|
|
AU2011239386B2
(en)
|
2010-04-16 |
2015-03-19 |
Salk Institute For Biological Studies |
Methods for treating metabolic disorders using FGF
|
|
EP3156062A1
(en)
|
2010-05-17 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Novel dna-binding proteins and uses thereof
|
|
WO2012015938A2
(en)
|
2010-07-27 |
2012-02-02 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
|
US8956646B2
(en)
|
2010-08-14 |
2015-02-17 |
The Regents Of The University Of California |
Zwitterionic lipids
|
|
EP2622090B1
(en)
|
2010-09-27 |
2019-06-19 |
Sangamo Therapeutics, Inc. |
Compositions for inhibiting viral entry into cells
|
|
CN103328496A
(en)
|
2010-10-25 |
2013-09-25 |
中央研究院 |
Cancer targeting peptides and their applications in cancer therapy and diagnosis
|
|
EP3461896B1
(en)
|
2011-07-15 |
2023-11-29 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
|
CA2853829C
(en)
|
2011-07-22 |
2023-09-26 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
IL293650B2
(en)
|
2011-09-21 |
2024-10-01 |
Sangamo Therapeutics Inc |
Methods and preparations for regulating transgene expression
|
|
MX374399B
(en)
|
2012-02-29 |
2025-03-06 |
Sangamo Biosciences Inc |
COMPOSITIONS AND THEIR USES FOR TREATING AND PREVENTING HUNTINGTON'S DISEASE.
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
AU2013289206B2
(en)
|
2012-07-11 |
2018-08-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
|
CA2878037C
(en)
|
2012-07-11 |
2021-08-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
|
ES2812599T3
(en)
|
2012-08-29 |
2021-03-17 |
Sangamo Therapeutics Inc |
Procedures and compositions for the treatment of a genetic condition
|
|
CA2886684C
(en)
|
2012-10-10 |
2023-09-19 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
EP3483185B1
(en)
|
2012-10-12 |
2020-09-09 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
EP3470061A1
(en)
|
2012-11-20 |
2019-04-17 |
Spectrum Pharmaceuticals, Inc. |
Improved method for the preparation of a dosage of liposome encapsulated vincristine for therapeutic use
|
|
WO2014089541A2
(en)
|
2012-12-07 |
2014-06-12 |
Haplomics, Inc. |
Factor viii mutation repair and tolerance induction
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
RU2721275C2
(en)
|
2012-12-12 |
2020-05-18 |
Те Брод Инститьют, Инк. |
Delivery, construction and optimization of systems, methods and compositions for sequence manipulation and use in therapy
|
|
IL300461A
(en)
|
2012-12-12 |
2023-04-01 |
Harvard College |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
|
EP2932421A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
US8993233B2
(en)
|
2012-12-12 |
2015-03-31 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
|
CN113528577B
(en)
|
2012-12-12 |
2024-12-03 |
布罗德研究所有限公司 |
Systems, methods and engineering of optimized guidance compositions for sequence manipulation
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
EP3825401A1
(en)
|
2012-12-12 |
2021-05-26 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
CN113005148A
(en)
|
2013-01-16 |
2021-06-22 |
爱默蕾大学 |
CAS 9-nucleic acid complexes and uses related thereto
|
|
CA2900338C
(en)
|
2013-02-07 |
2024-11-05 |
The General Hospital Corporation |
Tale transcriptional activators
|
|
EP2981551B1
(en)
|
2013-02-20 |
2020-06-03 |
Valerion Therapeutics, LLC |
Methods and compositions for treatment of pompe disease
|
|
EP3730615A3
(en)
|
2013-05-15 |
2020-12-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
EP3778899A1
(en)
|
2013-05-22 |
2021-02-17 |
Northwestern University |
Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
|
|
EP3004374B1
(en)
|
2013-06-07 |
2020-08-12 |
Massachusetts Institute of Technology |
Affinity-based detection of ligand-encoded synthetic biomarkers
|
|
KR20160044457A
(en)
|
2013-06-17 |
2016-04-25 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
EP3825406A1
(en)
|
2013-06-17 |
2021-05-26 |
The Broad Institute Inc. |
Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
CN105683379A
(en)
|
2013-06-17 |
2016-06-15 |
布罗德研究所有限公司 |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
AU2014281031B2
(en)
|
2013-06-17 |
2020-05-21 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components
|
|
KR20160034901A
(en)
|
2013-06-17 |
2016-03-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
EP3591045B1
(en)
|
2013-08-28 |
2024-07-17 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
CN116836957A
(en)
|
2013-10-17 |
2023-10-03 |
桑格摩生物科学股份有限公司 |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
WO2015070212A1
(en)
|
2013-11-11 |
2015-05-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
|
SI3068881T1
(en)
|
2013-11-13 |
2019-05-31 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
|
JP6883987B2
(en)
|
2013-12-04 |
2021-06-09 |
フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． |
Methods for wound healing procedures utilizing chemically modified oligonucleotides
|
|
CN105874071B
(en)
|
2013-12-09 |
2020-04-14 |
桑格摩生物科学股份有限公司 |
Methods and compositions for genome engineering
|
|
US20150166985A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting von willebrand factor point mutations
|
|
IL289736B2
(en)
|
2013-12-12 |
2025-09-01 |
Massachusetts Inst Technology |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
BR112016013213A2
(en)
|
2013-12-12 |
2017-12-05 |
Massachusetts Inst Technology |
administration, use and therapeutic applications of crisper systems and compositions for targeting disorders and diseases using particle delivery components
|
|
CN111269902A
(en)
|
2013-12-12 |
2020-06-12 |
布罗德研究所有限公司 |
Delivery and use of CRISPR-CAS systems and compositions
|
|
JP6793547B2
(en)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Optimization Function Systems, methods and compositions for sequence manipulation with the CRISPR-Cas system
|
|
HRP20201038T1
(en)
|
2014-02-03 |
2020-10-16 |
Sangamo Therapeutics, Inc. |
PROCEDURES AND PREPARATIONS FOR THE TREATMENT OF BETA THALASEMIA
|
|
AU2015231353B2
(en)
|
2014-03-18 |
2020-11-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
|
US20170051290A1
(en)
|
2014-05-01 |
2017-02-23 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
|
BR112016025849A2
(en)
|
2014-05-08 |
2017-10-17 |
Chdi Foundation Inc |
methods and compositions for the treatment of huntington's disease
|
|
CA2949713A1
(en)
|
2014-05-30 |
2015-12-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
|
AU2015277369B2
(en)
|
2014-06-16 |
2021-08-19 |
The Johns Hopkins University |
Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
|
|
WO2016011203A1
(en)
|
2014-07-15 |
2016-01-21 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
|
CA2954414A1
(en)
|
2014-07-15 |
2016-01-21 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
KR102330593B1
(en)
|
2014-07-28 |
2021-11-26 |
에스케이이노베이션 주식회사 |
Novel Isoprene Synthase and Method of Preparing Isoprene Using Thereof
|
|
EP3177718B1
(en)
|
2014-07-30 |
2022-03-16 |
President and Fellows of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
ES2780904T3
(en)
|
2014-08-17 |
2020-08-27 |
Broad Inst Inc |
Genomic editing using Cas9 nickases
|
|
KR102506169B1
(en)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
|
JP6722176B2
(en)
|
2014-09-16 |
2020-07-15 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for nuclease-mediated genomic engineering and correction in hematopoietic stem cells
|
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
IL234929B
(en)
*
|
2014-10-01 |
2021-01-31 |
Yeda Res & Dev |
Preparations containing liposomes and their use to prevent infections
|
|
EP3230452B1
(en)
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
EP3702456A1
(en)
|
2014-12-24 |
2020-09-02 |
The Broad Institute, Inc. |
Crispr having or associated with destabilization domains
|
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
|
EP3250691B9
(en)
|
2015-01-28 |
2023-08-02 |
Caribou Biosciences, Inc. |
Crispr hybrid dna/rna polynucleotides and methods of use
|
|
ES2959608T3
(en)
|
2015-04-03 |
2024-02-27 |
Dana Farber Cancer Inst Inc |
Composition and editing methods of the B cell genome
|
|
EP3294866A4
(en)
|
2015-05-12 |
2018-12-05 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
JP6985250B2
(en)
|
2015-05-16 |
2021-12-22 |
ジェンザイム・コーポレーション |
Gene editing of deep intron mutations
|
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
|
EP3303586A1
(en)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
EP4159856A1
(en)
|
2015-06-18 |
2023-04-05 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
|
EP3118216A1
(en)
|
2015-07-16 |
2017-01-18 |
Nuritas Limited |
Cellular growth and proliferation promoting peptides, and uses thereof
|
|
EP3118215A1
(en)
|
2015-07-16 |
2017-01-18 |
Nuritas Limited |
Anti-inflammatory peptides, and uses thereof
|
|
EP3117830A1
(en)
|
2015-07-16 |
2017-01-18 |
Nuritas Limited |
Antibacterial peptides, and uses thereof
|
|
KR102576571B1
(en)
|
2015-07-16 |
2023-09-11 |
뉴리타스 리미티드 |
Anti-inflammatory peptides, and uses thereof
|
|
EP3117831A1
(en)
|
2015-07-16 |
2017-01-18 |
Nuritas Limited |
Peptides for use in promoting transport of glucose into skeletal muscle
|
|
TWI678213B
(en)
|
2015-07-22 |
2019-12-01 |
美商史倍壯製藥公司 |
A ready-to-use formulation for vincristine sulfate liposome injection
|
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017062855A1
(en)
|
2015-10-09 |
2017-04-13 |
Monsanto Technology Llc |
Novel rna-guided nucleases and uses thereof
|
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
|
CA3024543A1
(en)
|
2015-10-22 |
2017-04-27 |
The Broad Institute, Inc. |
Type vi-b crispr enzymes and systems
|
|
SG10202104041PA
(en)
|
2015-10-23 |
2021-06-29 |
Harvard College |
Nucleobase editors and uses thereof
|
|
SG11201805157TA
(en)
|
2015-12-18 |
2018-07-30 |
Sangamo Therapeutics Inc |
Targeted disruption of the mhc cell receptor
|
|
CN108778297B
(en)
|
2015-12-18 |
2024-02-09 |
桑格摩生物治疗股份有限公司 |
Targeted destruction of T cell receptors
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
AU2017207818B2
(en)
|
2016-01-15 |
2024-03-28 |
Regents Of The University Of Minnesota |
Methods and compositions for the treatment of neurologic disease
|
|
EP3411056A4
(en)
|
2016-02-02 |
2019-10-02 |
Sangamo Therapeutics, Inc. |
COMPOSITIONS FOR BINDING DNA BINDING DOMAINS AND CLEAVAGE DOMAINS
|
|
EP3433263A4
(en)
|
2016-03-24 |
2019-10-23 |
Marquette University |
QUANTITATIVE FLAGELLAR FLUORESCENT MARKERS AND STANDARDS
|
|
CA3026055A1
(en)
|
2016-04-19 |
2017-10-26 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
AU2017253107B2
(en)
|
2016-04-19 |
2023-07-20 |
Massachusetts Institute Of Technology |
CPF1 complexes with reduced indel activity
|
|
US20200263190A1
(en)
|
2016-04-19 |
2020-08-20 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
CA3028074A1
(en)
|
2016-06-16 |
2018-12-20 |
Oslo Universitetssykehus Hf |
Improved gene editing
|
|
US11788083B2
(en)
|
2016-06-17 |
2023-10-17 |
The Broad Institute, Inc. |
Type VI CRISPR orthologs and systems
|
|
US20210222164A1
(en)
|
2016-06-29 |
2021-07-22 |
The Broad Institute, Inc. |
Crispr-cas systems having destabilization domain
|
|
CN109844116A
(en)
|
2016-07-05 |
2019-06-04 |
约翰霍普金斯大学 |
Including using H1 promoter to the improved composition and method of CRISPR guide RNA
|
|
ES2938210T3
(en)
|
2016-07-13 |
2023-04-05 |
Vertex Pharma |
Methods, compositions and kits to increase the efficiency of genome editing
|
|
US11674158B2
(en)
|
2016-07-15 |
2023-06-13 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
|
WO2018014936A1
(en)
|
2016-07-18 |
2018-01-25 |
Nuritas Limited |
Topical compositions
|
|
EP3494215A1
(en)
|
2016-08-03 |
2019-06-12 |
President and Fellows of Harvard College |
Adenosine nucleobase editors and uses thereof
|
|
JP2019528312A
(en)
|
2016-08-07 |
2019-10-10 |
ノバルティス アーゲー |
mRNA-mediated immunization methods
|
|
CN109804066A
(en)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
Programmable CAS9- recombination enzyme fusion proteins and application thereof
|
|
CN110312799A
(en)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
Novel C RISPR enzyme and system
|
|
US11352647B2
(en)
|
2016-08-17 |
2022-06-07 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
DK3504229T3
(en)
|
2016-08-24 |
2021-12-20 |
Sangamo Therapeutics Inc |
REGULATION OF GENEPRESSION USING MANIPULATED NUCLEASES
|
|
BR112019003327A2
(en)
|
2016-08-24 |
2019-07-02 |
Sangamo Therapeutics, Inc. |
specific target engineered nucleases
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
WO2018067826A1
(en)
|
2016-10-05 |
2018-04-12 |
Cellular Dynamics International, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
|
MA50839A
(en)
|
2016-10-13 |
2019-08-21 |
Juno Therapeutics Inc |
METHODS AND COMPOSITIONS OF IMMUNOTHERAPY INVOLVING MODULATORS OF THE TRYPTOPHAN METABOLIC PATHWAY
|
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
JP7042263B2
(en)
|
2016-10-20 |
2022-03-25 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for the treatment of Fabry disease
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
AU2017347928A1
(en)
|
2016-10-31 |
2019-05-09 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
US10011848B2
(en)
|
2016-11-09 |
2018-07-03 |
City University Of Hong Kong |
System and method for delivery of substance into mammalian cells
|
|
US11793833B2
(en)
|
2016-12-02 |
2023-10-24 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
|
EP4129321B1
(en)
|
2016-12-05 |
2025-10-15 |
Nuritas Limited |
Compositions comprising peptide wkdeagkplvk
|
|
EP3329905A1
(en)
|
2016-12-05 |
2018-06-06 |
Nuritas Limited |
Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
|
|
EP3329930A1
(en)
|
2016-12-05 |
2018-06-06 |
Nuritas Limited |
Pharmaceuctical compositions
|
|
ES2968892T3
(en)
|
2016-12-08 |
2024-05-14 |
Univ Case Western Reserve |
Methods and compositions to increase the production of functional myelin
|
|
US12404514B2
(en)
|
2016-12-09 |
2025-09-02 |
The Broad Institute, Inc. |
CRISPR-systems for modifying a trait of interest in a plant
|
|
WO2018119060A1
(en)
|
2016-12-20 |
2018-06-28 |
Bristol-Myers Squibb Company |
Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
CN110662556A
(en)
|
2017-03-09 |
2020-01-07 |
哈佛大学的校长及成员们 |
Cancer vaccine
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
KR20190127797A
(en)
|
2017-03-10 |
2019-11-13 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Cytosine to Guanine Base Editing Agent
|
|
US11795192B2
(en)
|
2017-03-10 |
2023-10-24 |
Lakewood Amedex, Inc. |
Antimicrobial compounds, compositions, and uses thereof
|
|
AU2018234825B2
(en)
|
2017-03-15 |
2020-12-17 |
Massachusetts Institute Of Technology |
Novel CAS13B orthologues CRISPR enzymes and systems
|
|
IL269458B2
(en)
|
2017-03-23 |
2024-02-01 |
Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
EP3607085A1
(en)
|
2017-04-07 |
2020-02-12 |
Massachusetts Institute Of Technology |
Methods to spatially profile protease activity in tissue and sections
|
|
KR20200006054A
(en)
|
2017-04-12 |
2020-01-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
New Type VI CRISPR Orthologs and Systems
|
|
WO2018195355A1
(en)
|
2017-04-19 |
2018-10-25 |
Rxi Pharmaceuticals Corporation |
Topical delivery of nucleic acid compounds
|
|
ES2981611T3
(en)
|
2017-04-28 |
2024-10-09 |
Univ Colorado Regents |
Methods for treating rheumatoid arthritis using RNA-guided genome editing of the HLA gene
|
|
WO2018208910A1
(en)
|
2017-05-09 |
2018-11-15 |
The Broad Institute Inc. |
Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
|
|
US11872262B2
(en)
|
2017-05-09 |
2024-01-16 |
Vib Vzw |
Means and methods for treating bacterial infections
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
US12297436B2
(en)
|
2017-05-18 |
2025-05-13 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
DK3538645T3
(en)
|
2017-06-20 |
2021-04-19 |
Inst Curie |
IMMUNE CELLS MISSING SUV39H1
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
IL271342B2
(en)
|
2017-06-23 |
2025-12-01 |
Inscripta Inc |
Nuclease systems guided by nucleic acids and methods for using them to modify target regions of a genome
|
|
WO2019005884A1
(en)
|
2017-06-26 |
2019-01-03 |
The Broad Institute, Inc. |
Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
|
AU2018338318B2
(en)
|
2017-09-21 |
2022-12-22 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
WO2019075292A1
(en)
|
2017-10-12 |
2019-04-18 |
Massachusetts Institute Of Technology |
Prostate cancer protease nanosensors and uses thereof
|
|
WO2019079347A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
WO2019084148A1
(en)
|
2017-10-25 |
2019-05-02 |
Monsanto Technology Llc |
Targeted endonuclease activity of the rna-guided endonuclease casx in eukaryotes
|
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
DK3710576T3
(en)
|
2017-11-17 |
2025-01-02 |
Iovance Biotherapeutics Inc |
TIL-EXPANSION FROM FIN NEEDLE ASPIRATES AND SMALL BIOPSIES
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
US20230193242A1
(en)
|
2017-12-22 |
2023-06-22 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
SG11202006541UA
(en)
|
2018-01-08 |
2020-08-28 |
Iovance Biotherapeutics Inc |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
AU2019209290B2
(en)
|
2018-01-17 |
2024-03-07 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
|
KR20200110685A
(en)
|
2018-01-17 |
2020-09-24 |
버텍스 파마슈티칼스 인코포레이티드 |
DNA-PK inhibitor
|
|
MA51623A
(en)
|
2018-01-17 |
2021-04-14 |
Vertex Pharma |
QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS AND KITS FOR INCREASING GENOME EDITING EFFICIENCY
|
|
WO2019160383A1
(en)
|
2018-02-19 |
2019-08-22 |
고려대학교 산학협력단 |
Vaccine comprising epitope of heat shock protein, and use thereof
|
|
WO2019173332A1
(en)
|
2018-03-05 |
2019-09-12 |
Massachusetts Institute Of Technology |
Inhalable nanosensors with volatile reporters and uses thereof
|
|
EP3784258A4
(en)
|
2018-04-25 |
2022-08-10 |
University of Massachusetts |
ARTIFICIAL EXOSOME COMPOSITION AND RELATED PROCEDURES
|
|
US12522811B2
(en)
|
2018-05-01 |
2026-01-13 |
The Children's Medical Center Corporation |
Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9
|
|
US12480140B2
(en)
|
2018-05-06 |
2025-11-25 |
Emendobio Inc. |
Differential knockout of an allele of a heterozygous ELANE gene
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
WO2019236566A1
(en)
|
2018-06-05 |
2019-12-12 |
Lifeedit, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
EP3820495A4
(en)
|
2018-07-09 |
2022-07-20 |
The Broad Institute Inc. |
RNA PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
|
|
KR20210056329A
(en)
|
2018-08-07 |
2021-05-18 |
더 브로드 인스티튜트, 인코퍼레이티드 |
New CAS12B enzyme and system
|
|
US12421507B2
(en)
|
2018-08-20 |
2025-09-23 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of CRISPR-CAS9
|
|
WO2020056343A1
(en)
|
2018-09-13 |
2020-03-19 |
Northwestern University |
Riboregulated switchable feedback promoter systems and methods
|
|
JP2022500052A
(en)
|
2018-09-18 |
2022-01-04 |
サンガモ セラピューティクス， インコーポレイテッド |
Programmed cell death 1 (PD1) specific nuclease
|
|
US12173349B2
(en)
|
2018-09-25 |
2024-12-24 |
Massachusetts Institute Of Technology |
Lung protease nanosensors and uses thereof
|
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
|
GB201815820D0
(en)
|
2018-09-28 |
2018-11-14 |
Univ Wageningen |
Off-target activity inhibitors for guided endonucleases
|
|
WO2020069373A1
(en)
|
2018-09-28 |
2020-04-02 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
|
EP3860618B1
(en)
|
2018-10-02 |
2026-02-04 |
Sangamo Therapeutics, Inc. |
Compositions for treating tauopathy
|
|
CA3116452A1
(en)
|
2018-10-15 |
2020-04-23 |
Fondazione Telethon |
Genome editing methods and constructs
|
|
EP3867396A2
(en)
|
2018-10-16 |
2021-08-25 |
Massachusetts Institute of Technology |
Renal clearable nanocatalysts for disease monitoring
|
|
WO2020081794A1
(en)
|
2018-10-17 |
2020-04-23 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Metastatic brain tumor targeting peptides
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
SG11202104663PA
(en)
|
2018-11-05 |
2021-06-29 |
Iovance Biotherapeutics Inc |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
|
US12343380B2
(en)
|
2018-11-05 |
2025-07-01 |
Iovance Biotherapeutics, Inc. |
Expansion of TILs utilizing AKT pathways inhibitors
|
|
MX2021004953A
(en)
|
2018-11-05 |
2021-08-11 |
Iovance Biotherapeutics Inc |
SELECTION OF IMPROVED TUMOR REACTIVE T CELLS.
|
|
CN113272421B
(en)
|
2018-11-05 |
2025-02-18 |
艾欧凡斯生物治疗公司 |
Methods for generating tumor-infiltrating lymphocytes and their use in immunotherapy
|
|
WO2020097610A1
(en)
|
2018-11-09 |
2020-05-14 |
Northwestern University |
Analytes' detection using regulated in vitro transcription
|
|
US12165743B2
(en)
|
2018-11-09 |
2024-12-10 |
The Broad Institute, Inc. |
Compressed sensing for screening and tissue imaging
|
|
US20220282275A1
(en)
|
2018-11-15 |
2022-09-08 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
|
CA3124110A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
|
JP7710372B2
(en)
|
2018-12-19 |
2025-07-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Methods for expanding tumor-infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
EP4339286A3
(en)
|
2018-12-27 |
2024-08-28 |
LifeEDIT Therapeutics, Inc. |
Polypeptides useful for gene editing and methods of use
|
|
WO2020146250A1
(en)
|
2019-01-07 |
2020-07-16 |
Dana-Farber Cancer Institute, Inc. |
SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS
|
|
WO2020150560A1
(en)
|
2019-01-17 |
2020-07-23 |
Massachusetts Institute Of Technology |
Sensors for detecting and imaging of cancer metastasis
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020163379A1
(en)
|
2019-02-05 |
2020-08-13 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
|
US11866469B2
(en)
|
2019-02-06 |
2024-01-09 |
Klogenix Llc |
DNA binding proteins and uses thereof
|
|
WO2020163307A1
(en)
|
2019-02-06 |
2020-08-13 |
Emendobio Inc. |
New engineered high fidelity cas9
|
|
US20230053540A1
(en)
|
2019-02-19 |
2023-02-23 |
Massachusetts Institute Of Technology |
Treatment of liver injury
|
|
WO2020180733A1
(en)
|
2019-03-01 |
2020-09-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
|
GB201903499D0
(en)
|
2019-03-14 |
2019-05-01 |
Ucl Business Plc |
Minimal promoter
|
|
US12534714B2
(en)
|
2019-03-18 |
2026-01-27 |
The Broad Institute, Inc. |
Type VII CRISPR proteins and systems
|
|
AU2020242032A1
(en)
|
2019-03-19 |
2021-10-07 |
Massachusetts Institute Of Technology |
Methods and compositions for editing nucleotide sequences
|
|
KR20210146986A
(en)
|
2019-04-02 |
2021-12-06 |
상가모 테라퓨틱스, 인코포레이티드 |
Methods of treating beta-thalassemia
|
|
EP3953461A4
(en)
|
2019-04-09 |
2023-05-31 |
The Regents of The University of California |
LONG-LASTING ANALGESIA THROUGH TARGETED EPIGENETIC SUPPRESSION IN VIVO
|
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
WO2020223539A1
(en)
|
2019-04-30 |
2020-11-05 |
The Broad Institute, Inc. |
Methods and compositions for barcoding nucleic acid libraries and cell populations
|
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US20220249701A1
(en)
|
2019-05-14 |
2022-08-11 |
The Broad Institute, Inc. |
Compositions and methods for targeting multinucleated cells
|
|
WO2020236972A2
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
US20220249697A1
(en)
|
2019-05-20 |
2022-08-11 |
The Broad Institute, Inc. |
Aav delivery of nucleobase editors
|
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
US20210317192A9
(en)
|
2019-05-29 |
2021-10-14 |
Massachusetts Institute Of Technology |
Hiv-1 specific immunogen compositions and methods of use
|
|
US11447790B2
(en)
|
2019-05-29 |
2022-09-20 |
Altria Client Services Llc |
Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers
|
|
GB201909597D0
(en)
|
2019-07-03 |
2019-08-14 |
Univ Wageningen |
Crispr type v-u1 system from mycobacterium mucogenicum and uses thereof
|
|
JP7735249B2
(en)
|
2019-07-23 |
2025-09-08 |
ムネモ・セラピューティクス |
SUV39H1-deficient immune cells
|
|
EP4010474A1
(en)
|
2019-08-08 |
2022-06-15 |
The Broad Institute, Inc. |
Base editors with diversified targeting scope
|
|
MX2022001849A
(en)
|
2019-08-12 |
2022-03-11 |
Lifeedit Therapeutics Inc |
NUCLEASES GUIDED BY RIBONUCLEIC ACID (RNA) AND THEIR ACTIVE FRAGMENTS AND VARIANTS AND METHODS OF USE.
|
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
|
EP4013873A1
(en)
|
2019-08-16 |
2022-06-22 |
Massachusetts Institute Of Technology |
Targeted trans-splicing using crispr/cas13
|
|
KR102099342B1
(en)
|
2019-09-03 |
2020-04-10 |
주식회사 제노포커스 |
Expression Method of CRM197 Protein
|
|
JP7780424B2
(en)
|
2019-10-10 |
2025-12-04 |
アルトリア クライアント サーヴィシーズ リミテッド ライアビリティ カンパニー |
The pale yellow locus in tobacco and its applications.
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
TW202130812A
(en)
|
2019-11-01 |
2021-08-16 |
美商聖加莫治療股份有限公司 |
Compositions and methods for genome engineering
|
|
JP2023501445A
(en)
|
2019-11-08 |
2023-01-18 |
フィオ ファーマシューティカルズ コーポレーション |
Chemically modified oligonucleotides targeting bromodomain-containing protein 4 (BRD4) for immunotherapy
|
|
WO2021108717A2
(en)
|
2019-11-26 |
2021-06-03 |
The Broad Institute, Inc |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
JP7758672B2
(en)
|
2019-12-20 |
2025-10-22 |
ノヴァロック バイオセラピューティクス， リミテッド |
Anti-interleukin-23 p19 antibodies and methods of use thereof
|
|
CA3163285A1
(en)
|
2019-12-30 |
2021-07-08 |
Alexandra Briner CRAWLEY |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2021138537A1
(en)
|
2019-12-31 |
2021-07-08 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved systemic delivery
|
|
GB202000934D0
(en)
|
2020-01-22 |
2020-03-04 |
Ucl Business Ltd |
Engineered immune cells
|
|
EP4097124A1
(en)
|
2020-01-28 |
2022-12-07 |
The Broad Institute Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
|
US20230235309A1
(en)
|
2020-02-05 |
2023-07-27 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
|
EP4100032B1
(en)
|
2020-02-05 |
2025-10-15 |
The Broad Institute, Inc. |
Gene editing methods for treating spinal muscular atrophy
|
|
CN115443124A
(en)
|
2020-02-05 |
2022-12-06 |
戴尔戴莫生物医疗有限公司 |
Artificial synapse
|
|
US20230079539A1
(en)
|
2020-02-10 |
2023-03-16 |
Board Of Regents, The University Of Texas System |
Methods for rapid cloning and expression of hla class i cells
|
|
EP4103687A4
(en)
|
2020-02-11 |
2024-03-20 |
Tenza, Inc. |
Bio-therapeutics for detection, diagnosis and treatment of diseases associated with mucosal bleeding
|
|
US20210262025A1
(en)
|
2020-02-18 |
2021-08-26 |
Massachusetts Institute Of Technology |
Multiplexed in vivo disease sensing with nucleic acid-barcoded reporters
|
|
TW202208626A
(en)
|
2020-04-24 |
2022-03-01 |
美商生命編輯公司 |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
EP4143315A1
(en)
|
2020-04-28 |
2023-03-08 |
The Broad Institute Inc. |
<smallcaps/>? ? ?ush2a? ? ? ? ?targeted base editing of thegene
|
|
EP4146794A1
(en)
|
2020-05-04 |
2023-03-15 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US12534744B2
(en)
|
2020-05-06 |
2026-01-27 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
|
AU2021268253A1
(en)
|
2020-05-06 |
2022-12-08 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
|
JP2023525304A
(en)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート，インコーポレーテッド |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
WO2021231437A1
(en)
|
2020-05-11 |
2021-11-18 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use
|
|
EP3939596A1
(en)
|
2020-07-14 |
2022-01-19 |
Bimeda Animal Health Limited |
A composition for treating helminth infestation in a mammal
|
|
WO2022015969A1
(en)
|
2020-07-15 |
2022-01-20 |
LifeEDIT Therapeutics, Inc. |
Uracil stabilizing proteins and active fragments and variants thereof and methods of use
|
|
EP4182297B1
(en)
|
2020-07-16 |
2025-09-03 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
EP4188395A1
(en)
|
2020-07-30 |
2023-06-07 |
Institut Curie |
Immune cells defective for socs1
|
|
US20230304047A1
(en)
|
2020-08-11 |
2023-09-28 |
University Of Oslo |
Improved gene editing
|
|
EP4501951A3
(en)
|
2020-08-25 |
2025-04-30 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
US20230331867A1
(en)
|
2020-09-04 |
2023-10-19 |
Novarock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
|
WO2022056139A1
(en)
|
2020-09-10 |
2022-03-17 |
Monsanto Technology Llc |
Increasing gene editing and site-directed integration events utilizing meiotic and germline promoters
|
|
AU2021339805A1
(en)
|
2020-09-11 |
2023-05-25 |
Life Edit Therapeutics, Inc. |
Dna modifying enzymes and active fragments and variants thereof and methods of use
|
|
US20230348892A1
(en)
|
2020-09-17 |
2023-11-02 |
Northwestern University |
Engineered mamalian genetic circuits and methods of using the same
|
|
US20230390371A1
(en)
|
2020-10-16 |
2023-12-07 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Anti-tumor immunity induces the presentation of aberrant peptides
|
|
AU2022206476A1
(en)
|
2021-01-11 |
2023-07-20 |
President And Fellows Of Harvard College |
Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
|
|
EP4284923A1
(en)
|
2021-01-29 |
2023-12-06 |
Wageningen Universiteit |
Crispr-associated base-editing of the complementary strand
|
|
JP2024505756A
(en)
|
2021-02-03 |
2024-02-07 |
アルトリア クライアント サーヴィシーズ リミテッド ライアビリティ カンパニー |
Methods for increasing trichome density and improving metabolite transport in plant trichomes
|
|
EP4304637A1
(en)
|
2021-03-12 |
2024-01-17 |
Synthego Corporation |
Genetically modified cells expressing antigen-containing fusion proteins and uses thereof
|
|
TW202300649A
(en)
|
2021-03-22 |
2023-01-01 |
美商生命編輯治療學公司 |
Dna modifying enzymes and active fragments and variants thereof and methods of use
|
|
CN117651564A
(en)
|
2021-04-14 |
2024-03-05 |
爱尔兰国立科克大学 |
Treatment of cerebrovascular events and neurological disorders
|
|
EP4322984A1
(en)
|
2021-04-14 |
2024-02-21 |
University College Cork-National University of Ireland Cork |
Psg1 for use in the treatment of osteoarthritis
|
|
WO2022243565A1
(en)
|
2021-05-21 |
2022-11-24 |
Cellectis S.A. |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
|
WO2022261509A1
(en)
|
2021-06-11 |
2022-12-15 |
The Broad Institute, Inc. |
Improved cytosine to guanine base editors
|
|
US20240271162A1
(en)
|
2021-06-11 |
2024-08-15 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|
|
JP2024529025A
(en)
|
2021-08-04 |
2024-08-01 |
フィオ ファーマシューティカルズ コーポレーション |
Chemically Modified Oligonucleotides
|
|
WO2023015309A2
(en)
|
2021-08-06 |
2023-02-09 |
The Broad Institute, Inc. |
Improved prime editors and methods of use
|
|
EP4408456A1
(en)
|
2021-10-01 |
2024-08-07 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Mammalian cardiac regeneration
|
|
WO2023076898A1
(en)
|
2021-10-25 |
2023-05-04 |
The Broad Institute, Inc. |
Methods and compositions for editing a genome with prime editing and a recombinase
|
|
AU2022375820A1
(en)
|
2021-11-01 |
2024-06-13 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
CN119120424A
(en)
|
2021-11-02 |
2024-12-13 |
辉大(上海)生物科技有限公司 |
A CRISPR-Cas12i system
|
|
WO2023080788A1
(en)
|
2021-11-05 |
2023-05-11 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Tryptophan depletion induces production and presentation of tryptophan to phenylalanine substitutions
|
|
WO2023096494A1
(en)
|
2021-11-26 |
2023-06-01 |
Synvolux Ip B.V. |
Conserved coronavirus t cell epitopes
|
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
|
JP2025501272A
(en)
|
2021-12-28 |
2025-01-17 |
ムネモ・セラピューティクス |
Immune cells with inactivated SUV39H1 and modified TCR
|
|
EP4466349A1
(en)
|
2022-01-24 |
2024-11-27 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
US20250163392A1
(en)
|
2022-02-02 |
2025-05-22 |
Inscripta, Inc. |
Nucleic acid-guided nickase fusion proteins
|
|
EP4504925A1
(en)
|
2022-04-04 |
2025-02-12 |
The Broad Institute, Inc. |
Cas9 variants having non-canonical pam specificities and uses thereof
|
|
CA3255225A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
|
JP2025511883A
(en)
|
2022-04-06 |
2025-04-16 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Reversing the aging of the central nervous system
|
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
|
JP2025515503A
(en)
|
2022-04-28 |
2025-05-15 |
ザ ブロード インスティテュート，インコーポレーテッド |
AAV vectors encoding base editors and uses thereof
|
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
|
AU2023269680A1
(en)
|
2022-05-13 |
2024-12-05 |
Northwestern University |
Receptor engagement-mediated enhancement of biologics delivery
|
|
WO2023220459A1
(en)
|
2022-05-13 |
2023-11-16 |
Northwestern University |
Active loading of cargo entity into lipid bilayer particles using dimerization domains
|
|
US20250313607A1
(en)
|
2022-05-13 |
2025-10-09 |
Northwestern University |
Synthetic modular extracellular sensors that employ natural receptor ligand-binding domains
|
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
EP4529560A1
(en)
|
2022-05-23 |
2025-04-02 |
Altria Client Services LLC |
Methods and compositions for regulating alkaloids in tobacco field
|
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
|
WO2023240137A1
(en)
|
2022-06-08 |
2023-12-14 |
The Board Institute, Inc. |
Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
|
|
EP4547826A1
(en)
|
2022-06-30 |
2025-05-07 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
|
WO2024015383A1
(en)
|
2022-07-12 |
2024-01-18 |
Northwestern University |
Engineered hypoxia biosensors and methods of using the same
|
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
|
US20240229054A9
(en)
|
2022-08-05 |
2024-07-11 |
Altria Client Services Llc |
Methods and compositions for regulating alkaloids in tobacco
|
|
WO2024033901A1
(en)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
JP2025531669A
(en)
|
2022-08-16 |
2025-09-25 |
ザ ブロード インスティテュート，インコーポレーテッド |
Evolved cytidine deaminases and methods for using same to edit DNA
|
|
TW202424186A
(en)
|
2022-08-25 |
2024-06-16 |
美商生命編輯治療學公司 |
Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
|
|
WO2024047587A1
(en)
|
2022-08-31 |
2024-03-07 |
Regel Therapeutics, Inc. |
Cas-phi compositions and methods of use
|
|
EP4601706A1
(en)
|
2022-10-11 |
2025-08-20 |
Massachusetts Institute of Technology |
Reagents and methods for the conditional delivery of cargo
|
|
EP4601669A1
(en)
|
2022-10-14 |
2025-08-20 |
University College Cork-National University of Ireland Cork |
Placenta expressed proteins for use in the treatment of tendon injury
|
|
AU2023374658A1
(en)
|
2022-11-03 |
2025-04-24 |
Cellectis S.A. |
Enhancing efficacy and safety of t-cell-mediated immunotherapy
|
|
JP2025537710A
(en)
|
2022-11-04 |
2025-11-20 |
ライフ エディット セラピューティクス，インコーポレイティド |
Evolved adenine deaminase and RNA-guided nuclease fusion proteins with internal insertion sites and methods of use
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
AU2023393442A1
(en)
|
2022-12-16 |
2025-07-31 |
Life Edit Therapeutics, Inc. |
Guide rnas that target trac gene and methods of use
|
|
WO2024127369A1
(en)
|
2022-12-16 |
2024-06-20 |
LifeEDIT Therapeutics, Inc. |
Guide rnas that target foxp3 gene and methods of use
|
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
|
GB202219855D0
(en)
|
2022-12-30 |
2023-02-15 |
Univ Oxford Innovation Ltd |
Affinity capture reagents for mass spectrometry
|
|
WO2024155597A1
(en)
|
2023-01-17 |
2024-07-25 |
Inscripta, Inc. |
Methods and compositions of co-expression of t7rna polymerase and inhibitory rna aptamers
|
|
WO2024163862A2
(en)
|
2023-02-03 |
2024-08-08 |
The Broad Institute, Inc. |
Gene editing methods, systems, and compositions for treating spinal muscular atrophy
|
|
WO2024214071A1
(en)
|
2023-04-12 |
2024-10-17 |
LifeEDIT Therapeutics, Inc. |
Compositions and methods for the treatment of huntington's disease by editing the mutant huntingtin gene
|
|
IT202300007968A1
(en)
|
2023-04-21 |
2024-10-21 |
Fond Telethon Ets |
Genome editing methods and constructs
|
|
WO2024234006A1
(en)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
|
|
WO2025004001A1
(en)
|
2023-06-30 |
2025-01-02 |
Takeda Pharmaceutical Company Limited |
Htt repressors and uses thereof
|
|
WO2025022367A2
(en)
|
2023-07-27 |
2025-01-30 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
EP4512403A1
(en)
|
2023-08-22 |
2025-02-26 |
Friedrich-Schiller-Universität Jena |
Neuropeptide b and w-receptor as a target for treating mood disorders and/or chronic stress
|
|
WO2025050069A1
(en)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Programmable gene insertion using engineered integration enzymes
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
WO2025075911A1
(en)
|
2023-10-02 |
2025-04-10 |
Inscripta, Inc. |
Engineered gpp synthases
|
|
WO2025080632A1
(en)
|
2023-10-11 |
2025-04-17 |
Altria Client Services Llc |
Compositions and methods to alter alkaloids in tobacco
|
|
WO2025083619A1
(en)
|
2023-10-18 |
2025-04-24 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and acive fragments and variants thereof and methods of use
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
WO2025122725A1
(en)
|
2023-12-06 |
2025-06-12 |
The Broad Institute, Inc. |
Methods and compositions for base editing of tpp1 in the treatment of batten disease
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
WO2025133254A2
(en)
|
2023-12-20 |
2025-06-26 |
Nuritas Limited |
Angiotensin-converting enzyme (ace) inhibiting peptides.
|
|
WO2025133189A1
(en)
|
2023-12-20 |
2025-06-26 |
Nuritas Limited |
Sleep promoting peptides and the use thereof
|
|
GB202400055D0
(en)
|
2024-01-03 |
2024-02-14 |
Tribune Therapeutics Ab |
Use of ccn domain-containing proteins for the treatment of disease
|
|
WO2025147604A1
(en)
|
2024-01-05 |
2025-07-10 |
Arbor Biotechnologies, Inc. |
Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1
|
|
WO2025147663A2
(en)
|
2024-01-05 |
2025-07-10 |
Altria Client Services Llc |
Methods and compositions for modulating trichome density and flavor molecule secretion
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025174908A1
(en)
|
2024-02-12 |
2025-08-21 |
Life Edit Therapeutics, Inc. |
Novel rna-guided nucleases and proteins for polymerase editing
|
|
WO2025176795A1
(en)
|
2024-02-20 |
2025-08-28 |
Centre Hospitalier Universitaire Vaudois (Chuv) |
T cell tracking
|
|
WO2025224107A1
(en)
|
2024-04-22 |
2025-10-30 |
Basecamp Research Ltd |
Method and compositions for detecting off-target editing
|
|
WO2025224182A2
(en)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
WO2025238184A1
(en)
|
2024-05-15 |
2025-11-20 |
Stichting Amsterdam UMC |
Scn10a-short gene therapy to restore cardiac impulse conduction and to protect against cardiac arrhythmia
|
|
WO2025242311A1
(en)
|
2024-05-23 |
2025-11-27 |
The University Of Bristol |
Cell populations and related methods
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|
|
WO2026003754A1
(en)
|
2024-06-25 |
2026-01-02 |
Life Edit Therapeutics, Inc. |
Novel reverse transcriptases and uses thereof
|
|
WO2026020031A2
(en)
|
2024-07-18 |
2026-01-22 |
Novarock Biotherapeutics, Ltd. |
Cdh17 antibodies and uses thereof
|